A new trading day began on Friday, with Verve Therapeutics Inc (NASDAQ: VERV) stock price up 11.24% from the previous day of trading, before settling in for the closing price of $5.16. VERV’s price has ranged from $4.30 to $19.34 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 126.44%. Meanwhile, its annual earnings per share averaged 21.22%. With a float of $63.10 million, this company’s outstanding shares have now reached $84.64 million.
The extent of productivity of a business whose workforce counts for 255 workers is very important to gauge. In terms of profitability, gross margin is 73.07%, operating margin of -928.6%, and the pretax margin is -806.35%.
Verve Therapeutics Inc (VERV) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Verve Therapeutics Inc is 25.47%, while institutional ownership is 76.15%. The most recent insider transaction that took place on Dec 02 ’24, was worth 3,130. In this transaction Chief Financial Officer of this company sold 555 shares at a rate of $5.64, taking the stock ownership to the 5,380 shares. Before that another transaction happened on May 14 ’24, when Company’s insider bought 76,000 for $6.26, making the entire transaction worth $475,760. This insider now owns 342,509 shares in total.
Verve Therapeutics Inc (VERV) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.73 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.22% per share during the next fiscal year.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Here are Verve Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 13.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.46, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -2.79 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
The latest stats from [Verve Therapeutics Inc, VERV] show that its last 5-days average volume of 2.18 million was superior to 1.37 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 16.63%. Additionally, its Average True Range was 0.57.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 42.77%, which indicates a significant increase from 30.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 105.87% in the past 14 days, which was higher than the 90.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.76, while its 200-day Moving Average is $6.48. Now, the first resistance to watch is $5.96. This is followed by the second major resistance level at $6.18. The third major resistance level sits at $6.60. If the price goes on to break the first support level at $5.32, it is likely to go to the next support level at $4.90. The third support level lies at $4.68 if the price breaches the second support level.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
With a market capitalization of 540.59 million, the company has a total of 84,664K Shares Outstanding. Currently, annual sales are 11,760 K while annual income is -200,070 K. The company’s previous quarter sales were 6,870 K while its latest quarter income was -50,130 K.
